| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2972972 | The Journal of Heart and Lung Transplantation | 2006 | 9 Pages |
Abstract
Compared with crystalloid or albumin, HES solutions enhance fibrinolysis by decreasing clot strength and decreasing the time of onset of fibrinolysis. Further studies are warranted to determine whether the fluid administered to patients with VADs can impact hemorrhagic and thrombotic morbidity.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Vance G. MD,